Expert Rev Anticancer Ther. 2012;12(1):41-49. © 2012 Expert Reviews Ltd. Uterine serous cancer (USC) is a highly aggressive variant of endometrial cancer. USC is ...
The authors were funded by NIH grants 1R01CA122728-01A4 and CA154460-01A1. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial ...
Zentalis Pharmaceuticals, Inc.’s ZNTL share price has dipped by 21.25%, which has investors questioning if this is right time ...
European Commission approves GSK’s Jemperli plus chemotherapy to treat patients with primary advanced or recurrent endometrial cancer: London, UK Tuesday, January 21, 2025, 09:0 ...
Equities research analysts at Wedbush boosted their FY2024 EPS estimates for shares of Zentalis Pharmaceuticals in a research note issued to investors on Wednesday, January 29th. Wedbush analyst R.
Zentalis Pharmaceuticals (NASDAQ:ZNTL – Free Report) had its price target decreased by UBS Group from $5.00 to $2.20 in a research report released on Tuesday,Benzinga reports. UBS Group currently has ...
They were on both ovaries, all over the uterus,” she says ... At first, doctors told her she had low-grade serous ovarian cancer, but she later learned she had borderline ovarian tumors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback